ML Research Intern, Genesis Therapeutics
Summer 2025
2+ days a week in office (Burlingame, CA)
Unifying AI and biotechnology for drug discovery
Be an early applicant
Unifying AI and biotechnology for drug discovery
21-100 employees
Be an early applicant
2+ days a week in office (Burlingame, CA)
21-100 employees
Company mission
To transform small molecule drug discovery to solve critical patient needs.
Role
Who you are
- A strong software engineer who will write code quickly and uphold our code quality standards
- A deep thinker who reasons from first principles over pattern matching
- Interested in learning about biochemistry and the drug development process
What the job involves
- Drive speed and accuracy improvements in our ML platform, coming up with architecture modifications for 2D and 3D graph neural networks, and rapidly implementing and testing them in pytorch
- Keep up with deep learning research, especially pertaining to graph neural nets and graph generative models, and quickly prototype ideas gleaned from the literature
- Dive deep into molecular datasets, creating statistically rigorous train, valid, and test sets to optimally train our models for real-world prediction and generation tasks
- Develop creative featurizations of 2D and 3D molecular structures that are inspired by laws of physics and chemistry, enabling our networks to take better advantage of available data
- Work closely with software engineers and medicinal chemists to make our ML platform maximally adaptive to different use cases
Our take
Genesis Therapeutics is at the forefront of advancing drug creation to foster better healthcare outcomes. the company offers an AI-powered molecule discovery platform, known as GEMS, designed to empower medical researchers. By seamlessly integrating AI with biotech, GEMS leverages deep learning and molecular simulations to explore uncharted territories within chemical space, unveiling novel opportunities for functional drugs.
Boasted to be the "industry's most advanced molecular AI platform", GEMS accelerates the discovery of small molecules while also enhancing potency and selectivity. This breakthrough capability not only expedites the development process but also paves the way for creating medications targeting previously inaccessible domains.
With significant funding backing its endeavours, Genesis Therapeutics is poised to transition into clinical testing. Moreover, the company aims to broaden the scope of its platform, extending its reach to encompass a wider array of therapeutic targets.
Kirsty
Company Specialist
Insights
Company
Funding (last 2 of 3 rounds)
Aug 2023
$224.1m
SERIES B
Dec 2020
$52m
SERIES A
Total funding: $280.2m
Company benefits
- Stock Option Eligibility
- 401(k) Plan
- Open PTO Policy
- Paid Company Holidays
- Free lunch and snacks at our offices
- Health Care Plan, including Medical, Dental, and Vision, fully covered for the employees
Company HQ
Country Club Manor, Hillsborough, CA
Articles
Leadership
Evan Feinberg
(CEO)PhD Graduate from Stanford, where they were an Algorithm Developer, collaborating with the Office of Technology Licensing to develop BraneRank (which uses graph substructures to rank search results). Was then a Deep Learning Consultant for Merck for 11 months.
Ben Sklaroff
(CTO)Graduated from UC Berkeley with a degree in Electrical Engineering and Computer Science. Worked at Markforged for 3 years, ultimately as Director of Software Engineering.
Salary benchmarks
We don't have enough data yet to provide salary benchmarks for this role.
Submit your salary to help other candidates with crowdsourced salary estimates.
Share this job
View 6 more jobs at Genesis Therapeutics